Abstract: Embodiments disclosed include systems and methods to generate and/or improve non-sporulating filamentous fungal cells using high-throughput techniques. Embodiments disclosed also include systems and methods for evaluation and iterative adjustment of methods to generate and/or isolate and select desired strains of non-sporulating filamentous fungal cells using high-throughput techniques.
Type:
Grant
Filed:
July 28, 2021
Date of Patent:
October 25, 2022
Assignee:
Zymergen Inc.
Inventors:
Benjamin Knox, Nasim Mansoori Zangir, Ryan Evan Martinez, Hassan Abdulla
Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
Type:
Grant
Filed:
March 24, 2022
Date of Patent:
October 18, 2022
Assignees:
The Regents of the University of California, University of Vienna
Inventors:
Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
Abstract: The present invention provides Streptomyces coelicolor strain A3(2)_M22-2C43 obtained by inducing a point mutation in the base sequence of the DagB gene in a wild-type Streptomyces coelicolor strain A3(2) by UV radiation. Since the Streptomyces coelicolor strain A3(2)_M22-2C43 according to the present invention expresses a DagB mutant enzyme expressing little or no DagB beta-agarase or exhibiting little or no beta-agarase activity, there is no need for separate isolation and purification of DagA enzymes from culture fluid, and the culture fluid of the Streptomyces coelicolor strain A3(2)_M22-2C43 or supernatant thereof may be used to produce, from agar or agarose, neoagarose oligosaccharides with a higher content of neoagarotetraose or neoagarohexaose than that of neoagarobiose.
Type:
Grant
Filed:
September 10, 2019
Date of Patent:
October 11, 2022
Assignee:
DYNEBIO INC.
Inventors:
Je Hyeon Lee, Eun Joo Kim, Yeon Hee Lee
Abstract: Methods, kits and compositions, in some embodiments, may include a thermostable DNA guided Argonaute protein for example TtAgo, a thermostable single-stranded DNA binding protein (SSB) for example, ET SSB, and, optionally, a strand-displacing polymerase. A SSB may allow (a) Argonaute/guide DNA complexes to substantially enhance cleavage efficiency of single- and double-stranded DNA substrates; (b) the use of longer guide DNAs (e.g., guide DNAs that are at least 24 nucleotides in length) and/or (c) increases in the sequence specificity of Argonaute-mediated binding and cleavage reactions.
Abstract: The present disclosure provides methods for detecting a single-stranded target RNA. The present disclosure provides methods of cleaving a precursor C2c2 guide RNA array into two or more C2c2 guide RNAs. The present disclosure provides a kit for detecting a target RNA in a sample.
Type:
Grant
Filed:
September 20, 2019
Date of Patent:
October 4, 2022
Assignee:
The Regents of the University of California
Inventors:
Jennifer A. Doudna, Mitchell Ray O'Connell, Alexandra East-Seletsky, Spencer Charles Knight, James Harrison Doudna Cate
Abstract: The present disclosure provides methods for detecting a single-stranded target RNA. The present disclosure provides methods of cleaving a precursor C2c2 guide RNA array into two or more C2c2 guide RNAs. The present disclosure provides a kit for detecting a target RNA in a sample.
Type:
Grant
Filed:
September 20, 2019
Date of Patent:
October 4, 2022
Assignee:
The Regents of the University of California
Inventors:
Jennifer A. Doudna, Mitchell Ray O'Connell, Alexandra East-Seletsky, Spencer Charles Knight, James Harrison Doudna Cate
Abstract: Provided are compositions and methods for detecting a target DNA (double stranded or single stranded) in a sample. In some embodiments, a subject method includes: (a) contacting the sample with: (i) a type V CRISPR/Cas effector protein (e.g., a Cas12 protein such as Cas12a, Cas12b, Cas12c, Cas12d, Cas12e); (ii) a guide RNA (comprising a region that binds to the type V CRISPR/Cas effector protein, and a guide sequence that hybridizes with the target DNA); and (iii) a detector DNA that is single stranded (i.e., a “single stranded detector DNA”) and does not hybridize with the guide sequence of the guide RNA; and (b) measuring a detectable signal produced by cleavage (by the type V CRISPR/Cas effector protein) of the single stranded detector DNA. Also provided are compositions and methods for cleaving single stranded DNAs (e.g., non-target ssDNAs), e.g., inside of a cell.
Type:
Grant
Filed:
July 13, 2020
Date of Patent:
September 20, 2022
Assignee:
The Regents of the University of California
Inventors:
Jennifer A. Doudna, Janice S. Chen, Lucas Benjamin Harrington, Enbo Ma
Abstract: The present disclosure provides improved long uniform recombinant protein fibers with desirable physical traits. The present disclosure also provides compositions derived from the long uniform recombinant protein fibers.
Type:
Grant
Filed:
September 14, 2017
Date of Patent:
September 20, 2022
Assignee:
BOLT THREADS, INC.
Inventors:
David Breslauer, Joshua Kittleson, Loren Perelman, Lindsay Wray
Abstract: The present disclosure provides methods of treating cancer in a patient determined to have an EGFR and/or HER2 exon 20 mutation, such as an insertion mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib or afatinib.
Type:
Grant
Filed:
November 17, 2017
Date of Patent:
September 20, 2022
Assignee:
Board of Regents, The University of Texas System
Inventors:
Jacqulyne Robichaux, Monique Nilsson, John V. Heymach
Abstract: The present disclosure provides methods and compositions for enhanced editing of genomic DNA. For example, in some embodiments, a subject method is a method of editing genomic DNA of a eukaryotic cell and the method includes introducing into a eukaryotic cell a composition comprising: (a) a linearized non-homologous DNA composition and (b) a genome targeting composition (which includes a genome editing endonuclease, or a nucleic acid encoding the genome editing endonuclease). In some cases in which the genome editing endonuclease is a CRISPR/Cas endonuclease, the genome targeting composition can also include a corresponding CRISPR/Cas guide RNA.
Type:
Grant
Filed:
January 11, 2017
Date of Patent:
August 30, 2022
Assignee:
The Regents of the University of California
Inventors:
Jacob Corn, Christopher D. Richardson, Graham Jordan Ray
Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of pl
Type:
Grant
Filed:
December 10, 2018
Date of Patent:
August 30, 2022
Assignee:
CSL BEHRING GmbH
Inventors:
Hung Pham, Jeffrey Michael Hey, Darren Nguy
Abstract: The present invention relates to a cell culture support comprising a substrate and a polymeric blend layer bound to the substrate. The polymeric blend layer comprises at least one thermoresponsive polymer and at least one coupling agent. The coupling agent is a non-protein coupling agent that has functional thiol, ester, epoxy, or aldehyde groups. The cell culture support further includes cells supported by the polymeric blend layer, wherein the thermoresponsive polymer provides for temperature induced detachment of the cells and/or cell sheets.
Abstract: Polyethylene glycol (PEG)-b-poly(?-amino ester) (PBAE) co-polymers (PEG-PBAE) and blends of PEG-PBAEs and PBAEs and their use for delivering drugs, genes, and other pharmaceutical or therapeutic agents safely and effectively to different sites in the body and to different cells, such as cancer cells, are disclosed.
Type:
Grant
Filed:
March 28, 2016
Date of Patent:
August 2, 2022
Assignee:
THE JOHNS HOPKINS UNIVERSITY
Inventors:
Jordan Green, Jayoung Kim, Stephany Tzeng
Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
Type:
Grant
Filed:
May 21, 2021
Date of Patent:
August 2, 2022
Assignees:
The Regents of the University of California, University of Vienna
Inventors:
Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
Abstract: The present disclosure provides CasY proteins, nucleic acids encoding the CasY proteins, and modified host cells comprising the CasY proteins and/or nucleic acids encoding same. CasY proteins are useful in a variety of applications, which are provided. The present disclosure provides CasY guide RNAs that bind to and provide sequence specificity to the CasY proteins, nucleic acids encoding the CasY guide RNAs, and modified host cells comprising the CasY guide RNAs and/or nucleic acids encoding same. CasY guide RNAs are useful in a variety of applications, which are provided. The present disclosure provides methods of identifying a CRISPR RNA-guided endonuclease.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
June 28, 2022
Assignee:
The Regents of the University of California
Inventors:
Jennifer A. Doudna, Jillian F. Banfield, David Burstein, Lucas Benjamin Harrington
Abstract: The present invention provides expression vectors for use in an inducible coexpression system, capable of controlled induction of expression of each gene product.
Type:
Grant
Filed:
September 11, 2016
Date of Patent:
June 28, 2022
Assignee:
ABSCI LLC
Inventors:
Sean McClain, Mark Valasek, Philip Barish, Jeremy Minshull
Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
Type:
Grant
Filed:
September 21, 2021
Date of Patent:
May 17, 2022
Assignees:
The Regenis of Wie University of California, University of Vienna
Inventors:
Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
Abstract: The present invention relates to a cell based genomic Recorded Accumulative Memory (geRAM) system (also referred to herein as Genomically Encoded Memory (GEM)) for recoding data (i.e., changes in nucleic acid sequences in cellular DNA in response to physical and/or chemical signal(s)) from the cellular environment.
Type:
Grant
Filed:
November 7, 2014
Date of Patent:
May 10, 2022
Assignees:
Massachusetts Institute of Technology, Whitehead Institute of Biomedical Research
Inventors:
Joseph M. Jacobson, Noah Jakimo, Naama Kanarek, David Sabatini
Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
Type:
Grant
Filed:
May 21, 2021
Date of Patent:
April 5, 2022
Assignees:
The Regents of the University of California, University of Vienna
Inventors:
Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier